Nonreplicating vectors in HIV vaccines

Current Opinion in HIV and AIDS

Volumn 8, Issue 5, 2013, Pages 412-420

  Johnson, Jennifer A ^a,c   Barouch, Dan H ^a,c   Baden, Lindsay R ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adenovirus; canarypox; HIV vaccine; nonreplicating vector; orthopoxvirus; vaccinia

Indexed keywords

ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; VIRUS VECTOR;

ADENOVIRUS 5; ALPHA VIRUS; CANARYPOX VIRUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; NONREPLICATING VECTOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOVIRUS; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS REPLICATION;

EID: 84883348835     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328363d3b7     Document Type: Review

References (64)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
2. Bart P, Goodall R, Barber T, et al. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc consortium. Vaccine 2008; 26:3153-3161.
3. McCormack S, Stohr W, Barber T, et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26:3162-3174.
4. National Institute Of Allergy And Infectious Diseases (NIAID). Evaluating the safety and immune response to three HIV vaccine schedules in healthy, HIVuninfected adults. ClinicalTrials.gov [Internet]. Bethesda, Maryland: National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine (US); 2000; Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01783977-term01783977&rank1 NLM Identifier: NCT01783977. [Accessed on 17 May 2013]
5. HIV Vaccine Trials Network. Evaluating the safety and priming response of an HIV vaccine regimen in healthy, HIV-uninfected adults. ClinicalTrials.gov [Internet]. Bethesda Maryland, National Library of Medicine (US): HIV Vaccine Trials Network National Library of Medicine (US); 2000 ; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01799954-term01799954&rank1 NLM Identifier: NCT01799954. [Accessed on 17 May 2013]
6. National Institute Of Allergy And Infectious Diseases (NIAID). Safety of and immune response to a prime-boost vaccine regimen in HIV-uninfected vaccine-naive adults. ClinicalTrials.gov [Internet]. Bethesda Maryland: National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine (US); 2000; Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00820846-term00820846&rank1 NLM Identifier: NCT00820846. [Accessed on 17 May 2013]
7. Keefer MC, Frey SE, Elizaga M, et al. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 2011; 29:1948-1958.
8. Goepfert PA, Elizaga ML, Sato A, et al. Phase I safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Inf Dis 2011; 203:610-619.
9. National Institute Of Allergy And Infectious Diseases (NIAID). Evaluating the safety and immune response of a prime-boost HIV vaccine regimen in healthy, HIV-uninfected, vaccinia-naive adults. ClinicalTrials.gov [Internet]. Bethesda Maryland: National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine (US); 2000; Available from: http://www. clinicaltrials. gov/ct2/show/NCT01571960-term01571960&rank1 NLM Identifier: NCT01571960. [Accessed on 2013 May 17]
10. Currier JR, Ngauy V, de Souza MS, et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010; 5:e13983.
11. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
12. FitzgeraldDW,Janes H, Robertson M, et al. Step Study Protocol Team. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (The Step Study). J Infect Dis 2011; 203:765-772.
13. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a doubleblind, randomized, placebo-controlled test-of-concept phase 2b study. Lancet Inf Dis 2011; 11:507-515.
14. National Institute of Allergy and Infectious Diseases (NIAID). Safety and effectiveness of HIV-1 DNA plasmid vaccine and HIV-1 recombinant adenoviral vector vaccine in HIV-uninfected, circumcised men and male-to-female (MTF) transgender persons who have sex with men. ClinicalTrials.gov [Internet]. Bethesda Maryland: National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine (US); 2000; Available from: http://www. clinicaltrials.gov/ct2/show/NCT00865566-termNCT00865566&rank1 NLM Identifier: NCT00865566. [Accessed on 17 May 2013]
15. National Institute of Allergy and Infectious Diseases (NIAID). STATEMENT: NIH discontinues immunizations in HIV vaccine study. NIAID.NIH.gov [Internet]. Bethesda Maryland: National Institute of Allergy nd Infectious Diseases (NIAID); 2013; Available from: http://www.niaid.nih.gov/news/newsreleases/2013/Pages/ HVTN505April2013.aspx. [25 April 2013]
16. Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 2013; 207:240-247.
17. Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013; 207:248-256.
18. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebocontrolled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLOS One 2012; 7:e41936.
19. International AIDS Vaccine Initiative; HIV Vaccine Trials Network; National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel Deaconess Medical Center; Ragon Institute of MGH, MIT and Harvard. Safety and immunogenicity study of Ad26-ENVA and Ad35-ENV HIV vaccines in healthy HIV-uninfected adults. ClinicalTrials.gov [Internet]. Bethesda (Maryland): HIV Vaccine Trials Network, National Library of Medicine (US); 2013 ; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01215149-term NCT01215149&rank1 NLM Identifier: NCT01215149. [Accessed on 17 May 2013]
20. National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the safety of and immune response to the VSV-Indiana HIV vaccine in healthy, HIV-uninfected adults. ClinicalTrials.gov [Internet]. Bethesda (Maryland): National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine (US); 2000 ; Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01438606-termNCT01438606&rank1 NLM Identifier: NCT01438606. [Accessed on 17 May 2013]
21. Kintu K, Andrew P, Musoke P, et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. J Acquir Immune Defic Syndr 2013; 63:1-8.
22. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006; 20:1481-1489.
23. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120. Negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203-212.
24. US Army Medical Research and Material Command; United States Army Medical Materiel Development Activity Armed Forces Research Institute of Medical Sciences, Thailand; Walter Reed Army Institute of Research (WRAIR); Sanofi Pasteur MSD; VaxGen; The EMMES Corporation; Ministry of Health, Thailand; Mahidol University; Royal Thai ArmyMedical Department; Tripler Army Medical Center; Henry M Jackson Foundation. HIV vaccine trial in Thai adults. ClinicalTrials.gov [Internet]. Bethesda (Maryland): US Army Medical Research and Material Command, National Library of Medicine (US); 2000; Available from: http://www.clinicaltrials.gov/ct2/show/NCT00223080-term NCT00223080&rank1 NLMIdentifierNCT00223080. [Accessed on 17 May 2013]
25. Rerks-Ngarm S, Paris RM, Chunsutthiwat S. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis 2013; 207:1195-1205.
26. Haynes BF, Gilbert PB, McElrath J, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Eng J Med 2012; 366:1275-1286.
27. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417-420.
28. US Army Medical Research and Materiel Command. Study of late boost strategies for HIV-uninfected participants from protocol RV 144. Clinical Trials.gov [Internet]. Bethesda (Maryland): US Army Medical Research and Materiel Command, National Library of Medicine (US); 2000; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01435135-term1435135& rank1 NLM Identifier: NCT01435135. [Accessed on 17 May 2013]
29. Harari A, Bart PA, Stohr E, et al. An HIV-1 clade C DNA prime NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63-77.
30. Harari A, Rozot V, Cavassini M, et al. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected ART-treated HIV patients. Eur J Immunol 2012; 42:3038-3048.
31. Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines 2011; 10:1221-1240.
32. Amato RJ, Stephankiw M. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncol 2012; 8:231-237.
33. Walsh SR, Wilck MB, Dominguez DJ, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoetic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 2013; 207:1888-1897.
34. Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010; 201:1361-1370.
35. Zhang X, Cassis-Ghavami F, Eller M, et al. Direct comparison of antigen production an induction of apoptosis by canarypox virus-and modified vaccinia virus Ankara-human immunodeficiency virus vaccine vectors. J Virol 2007; 81:7022-7033.
36. Walsh SR, Seaman MS, Grandpre LE, et al. Impact of antiorthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune response. Vaccine 2012; 31:114-119. Vector seropositivity does not affect immunogenicity for MVA-based vaccine
37. Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step study). J Infect Dis 2012; 206:258-266.
38. Chen H, Xiang ZQ, Li Y, et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 2010; 84:10522-10532.
39. Abbink P, Lemchert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-4663.
40. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human preexisting adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010; 28:950-957.
41. Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35 and 48 in pediatric and adult populations. Vaccine 2011; 29:5203-5209.
42. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV/AIDS 2010; 5:386-390.
43. Li H, Rhee EG, Masek-Hammerman K, et al. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol 2012; 86:10862-10865.
44. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132:397-409.
45. Lore K, Adams WC, Havenga MJ, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 2007; 179:1721-1729.
46. Perreau M, Welles HC, Pellaton C, et al. The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J Virol 2012; 86:6279-6285.
47. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol 2012; 86:9590-9598.
48. Penaloza-Macmaster P, Provine M, Ra L, et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 2013; 87:1373-1384.
49. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011; 3:81ra36.
50. Barouch DH, Liu J, Maxifeild LF, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
51. National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the safety and immune response of an adenovirus-based HIV vaccine in HIVuninfected adults. ClinicalTrials.gov [Internet]. Bethesda Maryland: National Institute of Allergy and Infectious Diseases (NIAID), National Library of Medicine (US); 2000; Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01103687-termNCT01103687&rank1 NLM Identifier: NCT01103687. [Accessed on 17 May 2013]
52. Ratto-Kim S, Currier JR, Cox JH, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLOS One 2012; 7:e45840.
53. International AIDS Vaccine Initiative. Safety and immunogenicity study of SeV-G(NP) HIV vaccine administered intranasally and Ad35-GRIN. HIV vaccine given intramuscularly in prime-boost regimens in HIV-uninfected volunteers. ClinicalTrials.gov [Internet]. Bethesda Maryland: International AIDS Vaccine Initiative, National Library of Medicine (US); 2000; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01705990-term NCT01705990&rank1 NLM Identifier: NCT01705990. [Accessed on 17 May 2013]
54. Dicks MD, Spencer AJ, Edwards NJ, et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012; 7:e40385.
55. Santra S, Sun Y, Korioth-Schmitz B, et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 2009; 27:5837-5845.
56. Roshorm Y, Cottingham MG, Potash MJ, et al. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur J Immunol 2012; 42:3243-3255.
57. O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205:772-781.
58. Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4:115ra2.
59. McKenna PM, Koser ML, Carlson KR, et al. Highly attenuated rabies virusbased vaccine vectors expressing simian-human immunodeficiency virus Env and simian immunodeficiency virus Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 2007; 195:980-988.
60. Tan GS, McKenna PM, Koser ML, et al. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 2005; 331:82-93.
61. Johnson KM, Vogel JE, Peralta PH. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 1966; 15:244-246.
62. Rao BL, Basu A, Wairagkar NS, et al. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh India, in 2003, associated with Chandipura virus. Lancet 2004; 364:869-874.
63. Cooper D, Wright KJ, Calderon PC, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008; 82:207-219.
64. Wecker M, Gilbert P, Russell N, et al. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 2012; 19:1651-1660.